Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis

被引：0

作者：

Catalano, John V.

Palumbo, Antonio

Weisel, Katja C.

Dimopoulos, Meletios A.

Delforge, Michel

Blade, Joan

Petrucci, Maria Teresa

Kropff, Martin

Hajek, Roman

Jacques, Christian

Yu, Zhinuan

Herbein, Lindsay

Cavo, Michele

机构：

[1] Monash Univ, Frankston Hosp, Melbourne, Vic 3004, Australia

[2] Monash Univ, Dept Clin Haematol, Melbourne, Vic 3004, Australia

[3] Univ Turin, Div Hematol, Turin, Italy

[4] Univ Hosp Tuebingen, Dept Med, Tubingen, Germany

[5] Univ Athens, Sch Med, GR-11527 Athens, Greece

[6] Katholieke Univ Leuven Hosp, Dept Hematol, Louvain, Belgium

[7] Hosp Clin Barcelona, Barcelona, Spain

[8] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00185 Rome, Italy

[9] Univ Munster, Munster, Germany

[10] Univ Hosp Ostrava, Sch Med, Ostrava, Czech Republic

[11] Univ Hosp Ostrava, Inst Clin Hematol, Ostrava, Czech Republic

[12] Celgene Corp, Summit, NJ USA

[13] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8544

引用

页数：1

共 23 条

[1] IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) INDUCTION FOLLOWED BY LEN MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: MM-015 POST-HOC ANALYSIS
Cavo, M.
Dimopoulos, M.
Palumbo, A.
Weisel, K.
Delforge, M.
Blade, J.
Petrucci, M.
Kropff, M.
Hajek, R.
Jacques, C.
Yu, Z.
Herbein, L.
Grote, L.
Catalano, J.
HAEMATOLOGICA, 2013, 98 : 330 - 331
[2] SAFETY PROFILE AND MANAGEMENT IN MM-015 COMPARING LENALIDOMIDE-MELPHALAN-PREDNISONE FOLLOWED BY LENALIDOMIDE MAINTENANCE (MPR-R) WITH MP AND MPR IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
Delforge, M.
Dimopoulos, M.
Adam, Z.
Hajek, R.
Yu, Z.
Herbein, L.
Jacques, C.
Palumbo, A.
HAEMATOLOGICA, 2012, 97 : 120 - 121
[3] THERAPY FOLLOWING RELAPSE ON MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) FOLLOWED BY LEN MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: EFFICACY AND SAFETY OF SECOND LINE LEN IN MM-015
Dimopoulos, M.
Petrucci, M.
Foa, R.
Catalano, J.
Kropff, M.
Yu, Z.
Her-bein, L.
Grote, L.
Jacques, C.
Palumbo, A.
HAEMATOLOGICA, 2013, 98 : 104 - 105
[4] A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015
Palumbo, Antonio
Adam, Zdenek
Kropff, Martin
Foa, Robin
Catalano, John
Gisslinger, Heinz
Wiktor-Jedrzejczak, Wieslaw
Delforge, Michel
Weisel, Katja
Cascavilla, Nicola
Van Droogenbroeck, Jan
Iosava, Genadi
Cavo, Michele
Blade, Joan
Beksac, Meral
Spicka, Ivan
Plesner, Torben
Yu, Zhinuan
Herbein, Lindsey
Mei, Jay
Jacques, Christian J.
Dimopoulos, Meletios Athanasios
BLOOD, 2011, 118 (21) : 220 - 221
[5] Efficacy of lenalidomide maintenance (LEN) therapy versus placebo, after melphalan, prednisone, bortezomib (MPV) induction therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM): The ARUMM (MM-026) trial
Hulin, Cyrille
Jacques, Christian
Bensmaine, Amine
Wortman-Vayn, Honeylet
Sun, Wei
Thakurta, Anjan
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[6] Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older
Palumbo, A. P.
Delforge, M.
Catalano, J.
Hajek, R.
Kropff, M.
Petrucci, M. T.
Yu, Z.
Mei, J. M.
Dimopoulos, M. A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[7] A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients
Palumbo, Antonio
Falco, Patrizia
Benevolo, Giulia
Rossi, Davide
Carella, Angelo Michele
Guglielmelli, Tommasina
Rocci, Alberto
De Paoli, Lorenzo
Grasso, Mariella
Siez, Maria Letizia Mosca
Piro, Eugenio
Caltagirone, Simona
Gay, Francesca
Cavallo, Federica
Gaidano, Gianluca
Boccadoro, Mario
BLOOD, 2010, 116 (21) : 808 - 808
[8] Treatment outcomes and healthcare resource utilization (HRU) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with lenalidomide (LEN) only or no maintenance: Connect MM registry.
Rifkin, Robert M.
Jagannath, Sundar
Durie, Brian G.
Shah, Jatin J.
Narang, Mohit
Terebelo, Howard R.
Gasparetto, Cristina
Toomey, Kathleen
Hardin, James W.
Wagner, Lynne I.
Parikh, Kejal
Abouzaid, Safiya
Srinivasan, Shankar
Kitali, Amani
Zafar, Faiza
Abonour, Rafat
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] MAINTENANCE THERAPY WITH LENALIDOMIDE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE EMN01 TRIAL
Magarotto, V.
Bringhen, S.
Offidani, M.
Benevolo, G.
Patriarca, F.
Palladino, C.
Falcone, A. P.
Rossi, D.
Villani, O.
Musolino, C.
Conticello, C.
Pulini, S.
Omede, P.
Zambello, R.
Guglielmelli, T.
Ledda, A.
Liberati, A. M.
Hajek, R.
Boccadoro, M.
Palumbo, A.
HAEMATOLOGICA, 2015, 100 : 82 - 82
[10] CMP-CARFILZOMIB (CFZ) PLUS MELPHALAN-PREDNISONE (MP)-IN ELDERLY PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF A PHASE (PH) I/II TRIAL
Moreau, P.
Kolb, B.
Hulin, C.
Caillot, D.
Benboubker, L.
Tiab, M.
Touzeau, C.
Leleu, X.
Roussel, M.
Chaleteix, C.
Attal, M.
Facon, T.
HAEMATOLOGICA, 2013, 98 : 97 - 97

← 1 2 3 →